Massive nodular melanoma: A case report

Dermatology Online Journal

Volumn 13, Issue 2, 2007, Pages

  Harting, Mandy ^a   Tarrant, William ^b   Kovitz, Craig A ^c   Rosen, Ted ^a   Harting, Matthew T ^b   Souchon, Eduardo ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PACLITAXEL; TEMAZOLAMIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC IMAGING; FAMILY HISTORY; HUMAN; HUMAN TISSUE; MALE; MEDICAL LITERATURE; MELANOMA; PHYSICAL EXAMINATION; PROGNOSIS; SKIN NECROSIS; TUMOR BIOPSY; BACK; FOLLOW UP; IMMUNOHISTOCHEMISTRY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; PALLIATIVE THERAPY; PATHOLOGY; RISK ASSESSMENT; SKIN TUMOR;

ADULT; BIOPSY, NEEDLE; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUMBOSACRAL REGION; MALE; MELANOMA; NEOPLASM STAGING; PALLIATIVE CARE; RISK ASSESSMENT; SKIN NEOPLASMS;

EID: 34248180097     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Jemal A, Murray, T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Rigel DS, Friedman RJ, Kopf AW: The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol. 1996;34:839-847.
3. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-30.
4. Freedberg I, Eisen A, Wolff K, et al: Fitzpatrick's Dermatology in General Medicine. 6th edition. 2003, p917-947.
5. MacKie RM: Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol. 2000;25:471-475.
6. Bergenmar M: Nodular histogenetic type - the most significant factor for thick melanoma: implications for prevention. Melanoma Res. 1998;8:403-411.
7. Weyers W, Euler M, Diaz-Cascajo C, et al: Classification of cutaneous malignant melanoma: a reassessment of histopathologic criteria for the distinction of different types. Cancer. 1999;86:288-299.
8. Legha SS, Ring S, Papadoupoulos N, et al: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989;64:2024-2029.
9. McClay EF, Mastrangelo MJ, Berd D, et al: Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer. 1992;50:553-556.
10. Reinhard D, Garbe C, Thompson JA, et al: Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma . J Clin Onc. 2006;2-4:1188-1194.
11. Wornom IL III, Smith JW, Soong SJ, et al: Surgery as palliative treatment for distant metastases of melanoma. Ann Surg. 1986;204:181-185.
12. Marks R: Epidemiology of melanoma.. Clin Exp Dermatol. 2000;25:459-463.
13. Richard MA: Melanoma and tumor thickness: the challenges of darly Diagnosis. Arch Dermatol. 1999;135:269-274.
14. Soong SJ: Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg. 1992;16:191-195.
15. Hughes TM, A'Hern RP, Thomas JM: Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br J Surg. 2000;87:892-901.
16. Karakousis CP, Velez A, Driscoll DL, Takita H: Metastasectomy in malignant melanoma. Surgery. 1994;115:295-302.
17. deGiorgi V, Massi D, Carli P: Giant melanoma displaying gross features reproducing parameters seen on dermoscopy. Dermatol Surg. 2002;28:646-648.
18. Benmeir P, Neuman A, Weinberg A, et al: Giant melanoma of the inner thigh: a homeopathic life-threatening negligence. Ann Plast Surg. 1991;27 (6):583-585.